The effect of antibacterial photothermal therapy on plaque in healthy adults
Not Applicable
Completed
- Conditions
- Infective dental diseases, mainly periodontitis and cariesOral Health
- Registration Number
- ISRCTN36318197
- Lead Sponsor
- niversity of Helsinki
- Brief Summary
2021 results in https://doi.org/10.3390/dj9050052 (added 01/06/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
1. Generally healthy
2. Age between 18 to 65
3. Ability to refrain from brushing one's teeth during the treatment period
4. Informed consent given
Exclusion Criteria
1. Diabetes
2. Medications that may affect the immune response or saliva secretion
3. Malignancy
4. Pregnancy
5. Dental implants or prosthesis
6. Fixed orthodontic appliances
7. An active or a chronic oral infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the plaque area after the treatment period in treated and untreated teeth, measured using indocyanine green and photography under near-infrared lighting and white light lighting conditions; images taken daily during the 4-day study period
- Secondary Outcome Measures
Name Time Method <br> 1. The amount of plaque measured as an area on the dental surface, measured using indocyanine green and photography under near-infrared lighting and white light lighting conditions (images taken daily during the 4-day study period)<br> 2. The percentage of plaque area of the selected dental surface area, measured using indocyanine green and photography under near-infrared lighting and white light lighting conditions (images taken daily during the 4-day study period)<br> 3. Amount of MMP-8 in gingival crevicular fluid by a time-resolved immunofluorescence assay pre-and post-intervention (samples taken daily during the 4-day study period)<br> 4. 16S bacteriological ecology pre- and post-intervention: V3-V4 regions of the 16S rRNA genes amplified and sequenced with an Illumina MiSeq sequencer (San Diego, CA, USA) (samples taken at day 0 (preintervention) and at day 4 (postintervention) of the study)<br>